- Innovation (NYSE:VAT) announced today that the US Food and Drug Administration has approved the MediBeacon TGFR for the assessment of renal function in patients with normal or impaired renal function.
- TGFR met its FDA-agreed primary efficacy endpoint demonstrating a P30 value of 94% while enrolling patients with a range of GFR values and skin tones.
